Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bezisterim
- Development stage
- Phase 3
- Lead developer
- BioVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bezisterim (NE3107) is an investigational, orally bioavailable small molecule being developed by BioVie for the treatment of Long COVID, Alzheimer's disease, and Parkinson's disease. It acts as an anti-inflammatory and insulin-sensitizing agent that effectively crosses the blood-brain barrier. Its primary mechanism involves inhibiting Toll-like receptor 4 (TLR-4) driven activation of nuclear factor kappa B (NFκB) and modulating extracellular signal-regulated kinase (ERK) signaling. By targeting these pathways, bezisterim reduces the expression of pro-inflammatory cytokines such as IL-6, TNF, and IFNγ without being immunosuppressive. In Long COVID, it is specifically being evaluated for its potential to alleviate neurocognitive symptoms ("brain fog") and fatigue.
- Brand names
- Bezisterim
- Other names
- Triolex
02
Targets
MAPK3 (Mitogen-activated protein kinase 1)LRP1 (Prolow-density lipoprotein receptor-related protein 1)RPS6KA3 (RSK2)SIRT2 (NAD-dependent protein deacetylase sirtuin-2)NF-κBTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on bezisterim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bezisterim.